Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC - Top-Institutions - DentalSpire

Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC

  • By

  • Dongmei Ji

  • Wenmin Fu

  • Yonghong Liu

  • Weina Shen

  • Muyu Kuang

  • Zhouyu Ning

  • Youzhou Sang

  • Guangliang Chen

  • Jian Zhang

  • Zijie Zhou

  • Dashuang Xu

  • Xu Jin

  • Junlong Wu

  • Xusha Zhou

  • Jing Zhao

  • Lei Wang

  • Yukun Liu

  • Xi Zhang

  • Runbin Yan

  • Xiaoqing Chen

  • Grace Zhou

  • Jiaxin Niu

  • Xichun Hu

  • February 20, 2026

  • 0 min

Share

Top Institutions in Dental

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Head and Neck Oncology
    • Immunotherapy
    • Clinical Trials
    • Oncolytic Virus Therapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Head and Neck Oncology
    • Immuno-Oncology
    • Oncolytic Virus Research

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Immunotherapy
    • Head and Neck Cancer

  • #4

    University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center
    University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center

    Los Angeles, CA

    Key Differentiators

    • Head and Neck Oncology
    • Immunotherapy
    • Oncolytic Virus Therapy

  • #5

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Head and Neck Oncology
    • Immunotherapy
    • Translational Cancer Research

Original Source(s)

Phase 1/2a Clinical Trial of T3011, an Oncolytic HSV Delivering IL-12 and PD-1 Antibody, Administered Intratumorally as a Monotherapy for Advanced Solid Tumors, Including Recurrent or Metastatic HNSCC

  • by Dongmei Ji, Wenmin Fu, Yonghong Liu, Weina Shen, Muyu Kuang, Zhouyu Ning, Youzhou Sang, Guangliang Chen, Jian Zhang, Zijie Zhou, Dashuang Xu, Xu Jin, Junlong Wu, Xusha Zhou, Jing Zhao, Lei Wang, Yukun Liu, Xi Zhang, Runbin Yan, Xiaoqing Chen, Grace Zhou, Jiaxin Niu, Xichun Hu

  • February 20, 2026

Related Content

Consensus Guidance May Improve Sinonasal Mass Outcomes

Multidisciplinary recommendations emphasize biopsy technique, imaging, and pathology review in patients with suspected sinonasal malignancy.

One Day Jaw Reconstruction

Jaw surgery for cancer patients and others can sometimes take several years to be completed, with the patient undergoing multiple procedures to place a prosthetic, secure and attach dental implants and undergo treatment for their disease.

  • June 26, 2023

  • 3 min
Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.